Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01459653 · OUTCOME

EP2006 Dose (Cycle 5)

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor · Source last updated 2016-01-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Cycle 5. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.

What was measured

Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.

Analysis population: Number of participants at cycle 5 with dose data

Groups in this outcome

EP2006

Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
EP2006862

Reported measurements

30 MIU/day
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006431Not reportedNot reportedNot reportedNot reported
48 MIU/day
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006424Not reportedNot reportedNot reportedNot reported
Other
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP20067Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        431
    title
    30 MIU/day
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        424
    title
    48 MIU/day
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Other
denoms
  1. counts
    1. group Id
      OG000
      value
      862
    units
    Participants
description
Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.
groups
  1. description
    Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
    id
    OG000
    title
    EP2006
param Type
NUMBER
population Description
Number of participants at cycle 5 with dose data
reporting Status
POSTED
time Frame
Cycle 5. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.
title
EP2006 Dose (Cycle 5)
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice